Managing Director, D.E. Shaw and Co., L.P.
Vice President for Corporate Engagement, Rose-Hulman Institute of Technology
Vice president, chief strategy and operating officer of the Texas Medical Center
CEO and Fund Manager, Renaissance Venture Capital Fund
|Hologic, Fending off Icahn, Adopts Poison Pill to Deflect Takeover||Ben Fidler||11/21/13||Boston|
|6 Goals for Fixing Genzyme: Xconomy’s Q&A With Relational Investors’ Ralph Whitworth||Bruce V. Bigelow||01/21/10||San Diego|
|VentiRx Pharmaceuticals Raises More Funds, Genzyme Declares a Truce, Adventrx Charts Comeback, & More San Diego Life Sciences News||Denise Gellene||01/14/10||San Diego|
|Page 1 of 1|